Cite
KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE
MLA
Susannah J. Tye, et al. “Ketamine for Treatment-Resistant Unipolar and Bipolar Major Depression: Critical Review and Implications for Clinical Practice.” Depression and Anxiety, vol. 33, Apr. 2016, pp. 698–710. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ed131ba194d187f2407862b64ad22535&authtype=sso&custid=ns315887.
APA
Susannah J. Tye, William V. Bobo, Paul E. Croarkin, Jonathan G. Leung, Mark A. Frye, & Jennifer L. Vande Voort. (2016). Ketamine for Treatment-Resistant Unipolar and Bipolar Major Depression: Critical Review and Implications for Clinical Practice. Depression and Anxiety, 33, 698–710.
Chicago
Susannah J. Tye, William V. Bobo, Paul E. Croarkin, Jonathan G. Leung, Mark A. Frye, and Jennifer L. Vande Voort. 2016. “Ketamine for Treatment-Resistant Unipolar and Bipolar Major Depression: Critical Review and Implications for Clinical Practice.” Depression and Anxiety 33 (April): 698–710. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ed131ba194d187f2407862b64ad22535&authtype=sso&custid=ns315887.